Description
Atuveciclib (BAY-1143572) is a potent, highly selective, orally bioavailable CDK9/P-TEFb inhibitor with IC50 of 6nM for CDK9/CyclinT1; displays >150-fold selectivity over CDK1/2/3/5/6/7 (IC50>800nM), also shows submicromolar inhibitory activity against GSK3alpha (IC50=45nM), GSK3beta (IC50=87nM); demonstrates antiproliferative activity against HeLa cells (IC50=920nM) and MOLM" 13 cells (IC50=310nM); exhibits anticancer activity in human AML models. Blood Cancer Phase 1 Clinical